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Human papillomavirus (HPV) infection has a
well established association with the development
of genital warts andmany types of cancer, including
cervical, anal, oropharyngeal, and penile cancer.[2,3]
It is the most common sexually transmitted infec-
tion in the US,[2] with an annual prevalence of 1%
of the sexually active population.[3] It has been
estimated that 80% of sexually active women will
acquire HPV infection by the time they are aged
50 years.[2] Rates among men are also high, with
estimates of »65–70% of males being infected
with HPV.[4] Young people appear to be most at
risk, with 74% of annual HPV infections occur-
ring in men and women aged 14–24 years.[2]
While most HPV infections are transient,[2,3]
»10% lead to persistent infection.[2] Approximately
40 of the >100 knownHPV types have been shown
to infect the anogenital tract.[2,3] Fifteen of these
have been identified as high-risk (including HPV
16 and 18) and twelve as low-risk (including HPV
6 and 11);[2] HPV 6 and 11 are strongly associated
with genital warts (>90% association[3]), while HPV
16 and 18 are strongly associated with cervical and
anogenital cancers.[2,3] A total of 99.7% of cervical
cancers have detectable levels of HPV DNA,[2] and
almost 90% of vaginal cancers are associated with
HPV.[5] In men, 80–85% of anal cancers[5] and al-
most 50% of penile cancers[5,6] are associated with
HPV infection.
The rate of new cases of anogenital warts is in-
creasing; currently, more than 500 000 new cases
occur in the US annually, and a 2003 estimate
found that »1.4million people in the US had
genital warts.[3] Moreover, results from a recent
study have suggested that the incidence and preva-
lence of genital warts may be becoming higher in
men than in women.[7] The societal burden of
genital warts, in terms of both cost and loss of
quality of life, is significant.[8-10]
The quadrivalent HPV types 6, 11, 16, 18 vaccine
(Gardasil; hereafter referred to as the quadrivalent
HPV vaccine) is a noninfectious recombinant vac-
cine and comprises purified virus-like particles de-
rived from the L1 capsid proteins of HPV types 6,
11, 16, and 18.[11] Each dose contains approx-
imately 20, 40, 40, and 20 mg of each virus-like
particle type, respectively, and includes 225 mg of
amorphous aluminium hydroxyphosphate sul-
fate adjuvant (AAHS).[11] It was approved in fe-
males in the US in 2006[12] for the prevention of
various diseases caused by HPV types 6, 11, 16,
and 18, and has recently been approved in males
for the prevention of genital warts caused byHPV
types 6 and 11.[11] Over 61million doses of the
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quadrivalent HPV vaccine have been distributed
worldwide.[13] The features and properties of the
quadrivalentHPV vaccine are presented in table I.[1]
The quadrivalent vaccine has demonstrated
efficacy in the prevention of cervical, vulvar, and
vaginal cancer, genital warts, and precancerous
or dysplastic lesions caused by HPV types 6, 11,
16, and 18 in females,[11] and estimates show that,
as well as being potentially cost effective,[14] na-
tional vaccination programs targeting adolescent
females and young women can be expected to
result in decreased incidences of HPV infection[15]
and genital warts[16] in both females and hetero-
sexual males (HM) as a result of herd immunity.[16]
However, no change was predicted for men who
have sex with men (MSM; a group with a high
prevalence of HPV infection[17]) or females outside
the age range for vaccination.[16]
Various arguments exist in favor of nationwide
vaccination of males as well as females, including
the increased likelihood of herd immunity, in-
creased effect in the MSM population, and de-
creased incidence of HPV-associated disease in
males (potentially more so than is associated with
decreased transmission of the virus from fe-
males).[12,18] While one analysis indicated that the
vaccination of males as well as females may not
be cost effective in the US,[19] this study assumed
a higher vaccination rate (75% in both sexes) than
is currently observed in women in the US and in
most other countries,[12] mainly focused on the
prevention of cervical cancer (only including other
factors [e.g. genital warts, lower vaccination rates]
in secondary scenarios),[19] and did not specifically
include MSM in any analyses.[19] Other analyses
were more positive, one citing substantial public
health benefits and cost effectiveness of vaccinating
males aged 9–26 years against HPV 6-, 11-, 16-,
and 18-related diseases,[20] another finding that
vaccinating MSMwas a cost-effective method for
prevention of HPV-related anal cancer and genital
warts.[21] It has been suggested that if vaccination
of one sex falls below 75%, both sexes will need
to be vaccinated to achieve herd immunity.[18]
Nevertheless, debate continues as to the necessity
of vaccination in males.
The quadrivalent HPV vaccine is a recombi-
nant vaccine comprising purified virus-like par-
ticles derived from the L1 capsid proteins of HPV
types 6, 11, 16, and 18.[11]
The vaccine was highly immunogenic in
males.[22-25] Geometric mean titers (GMTs) and
seroconversion rates for all four HPV types at
month 7 inmales aged 10–15 years were noninferior
to those in females aged 16–23 years,[22] and those in
males aged 9–15 years were noninferior to those in
females aged 9–15 years.[23] In addition, GMTs
and seroconversion rates inmales aged 16–26 years
receiving the vaccine were higher than in those re-
ceiving AAHS control.[25]
Immunogenicity was generally maintained in
the longer term (18–37 months), although antibody
levels decreased substantially, compared with the
levels at month 7.[11,23,25]
Immunogenicity of the quadrivalent HPV vac-
cine was not affected by coadministration with a
diptheria, tetanus, pertussis, and poliomyelitis vac-
cine (Repevax),[26] ameningococcal polysaccharide
conjugate vaccine (Menactra) plus a tetanus, dip-
theria, and pertussis vaccine (Adacel),[27] or a te-
tanus, diptheria, and pertussis vaccine (Boostrix)
plus an investigational quadrivalent meningococcal
glycoconjugate vaccine[28] in three randomized,
open-label trials in mixed-sex populations aged
Table I. Features and properties of the quadrivalent human papil-
lomavirus (HPV) types 6, 11, 16, 18 vaccine (Gardasil)[1]
Featured indication
Prevention of genital warts (condyloma acuminata) caused by
infection with HPV types 6 and 11 in males aged 9–26 y
Vaccine composition
Virus-like particles (VLPs) derived from the L1 capsid proteins of
HPV types 6, 11, 16, and 18
Formulated with a proprietary amorphous aluminium





Dose 0.5mL (containing 20, 40, 40, and
20 mg of VLPs for HPV types 6, 11,
16, and 18, respectively)
Administration
schedule
Three-dose regimen; injections at
months 0, 2, and 6
Most common adverse events (‡5% of males aged 9–26 years
receiving the quadrivalent HPV vaccine)
Injection-site pain, injection-site erythema, injection-site swelling,
headache, pyrexia
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11–17,[26] 10–17,[27] and 11–18[28] years. Moreover,
the immune responses related to the other vaccines
being investigated were also noninferior with con-
comitant versus sequential administration.[26-28]
Additionally, neither of the immune responses
associated with the quadrivalent HPV vaccine or
a hepatitis B vaccine (Recombivax HB) were
affected when the vaccines were coadministered
in a population of women aged 16–23 years.[29]
After a median follow-up of 2.9 years, the
quadrivalent HPV vaccine was significantly more
effective than AAHS control at decreasing the
incidence of HPV 6-, 11-, 16-, or 18-related external
genital lesions (the primary endpoint) in a random-
ized, double-blind, placebo-controlled, multicenter
study inmales aged 16–26 years.[24] The vaccine was
90.4% effective (95% CI 69.2, 98.1) for this end-
point. The most common clinical endpoint was
HPV 6- and 11-related condyloma; efficacy was
robust against these lesions.[24] No cases of penile/
perianal/perineal cancer were reported in either
group.[25]
The vaccine is also expected to be protective
against genital warts in males aged 9–15 years, as
the immune response in males of this age group was
noninferior to that in males aged 16–26 years.[25]
Efficacy of the quadrivalent HPV vaccine was
also shown with regard to the prevention of per-
sistent and incident HPV infection.[24]
The quadrivalent HPV vaccine was generally
well tolerated in males aged 9–26 years.[22-24] The
most common adverse events reported were in-
jection-site related,[22-24] and most of these were
of mild to moderate severity.[11] Overall, coad-
ministration of the quadrivalent HPV vaccine with
other vaccines was generally well tolerated.[26-29]
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